Benefits
Acute toxin decontamination (poisoning emergency)
The 2021 Hoegberg systematic review by the Clinical Toxicology Recommendations Collaborative concluded that activated charcoal benefits patients with acute oral poisoning when administered beyond one hour in many clinical scenarios — challenging earlier strict 1-hour cutoff. Most useful for: tricyclic antidepressants, theophylline, phenobarbital, carbamazepine, dapsone, and salicylates. Routine administration for all overdoses does not change outcomes.
Intestinal gas reduction (modest evidence)
Hall 1981 and follow-up studies show activated charcoal reduces breath hydrogen excretion and flatus passage after gas-producing meals (e.g., bean ingestion). Effect is modest. Charcocaps® (250 mg) is widely sold OTC for occasional gas/bloating with FDA GRAS recognition for this use. The 2024 Charcocaps RCT in healthy adults tested 250 mg capsules vs placebo on breath hydrogen and gastrointestinal symptoms after high-fiber meal.
Reduction of uremic toxin absorption (chronic kidney disease)
AST-120 (Kremezin), a refined activated charcoal formulation, has been studied for slowing CKD progression by adsorbing indoxyl sulfate and p-cresyl sulfate. Several Asian RCTs show slowed eGFR decline; large Western trials (EPPIC) did not confirm benefit. Approved in Japan, Korea, and Philippines for CKD. Different from generic activated charcoal.
Mechanism of action
Non-specific surface adsorption
Activated charcoal has an extraordinarily high surface area (800-1,200 m²/g) created by pyrolysis followed by oxidizing gas exposure at high temperatures. This surface adsorbs a wide range of organic and some inorganic compounds via van der Waals forces. Adsorption is non-specific — affecting drugs, toxins, gases, and dissolved compounds within the GI lumen.
Interruption of enterohepatic recirculation
Multiple-dose activated charcoal (MDAC) creates a 'gut dialysis' effect — bound drug or toxin in the gut prevents reabsorption of compounds undergoing enterohepatic recirculation (cycling between gut and liver via bile). This mechanism is the rationale for MDAC in poisoning by phenobarbital, theophylline, dapsone, and similar drugs even after they're already absorbed systemically.
Adsorption of fermentation gases
Charcoal adsorbs hydrogen, methane, and other gases produced during colonic fermentation of carbohydrates. The reduction in gas pressure and volume produces the modest anti-flatulence effect. Note: some absorbed gases pass to systemic circulation regardless — adsorption is partial.
Clinical trials
Systematic review by Clinical Toxicology Recommendations Collaborative (Hoegberg LCG, Shepherd G, Wood DM, Johnson J, Hoffman RS, Caravati EM, Chan WL, Smith SW, Olson KR, Gosselin S 2021, Clin Toxicol (Phila) 59(12):1196-1227, doi:10.1080/15563650.2021.1961144).
Comprehensive review of all available evidence on oral activated charcoal in adult and pediatric poisoning. Combined data from controlled studies (n=2,359 within 1 hour) and clinical reports (n=1,006 beyond 1 hour).
Heterogeneous data with higher-quality evidence for select poisonings (anticonvulsants, salicylates, calcium channel blockers, paraquat). Despite limitations, benefit reported beyond one hour in many clinical scenarios — challenging strict 1-hour cutoff from earlier guidelines. Authors recommended individualized assessment based on toxin properties, time since ingestion, and patient stability.
Randomized clinical trial of routine vs no-routine activated charcoal (Cooper GM, Le Couteur DG, Richardson D, Buckley NA 2005, QJM 98(9):655-660, PMID 16040667).
327 adult patients with oral drug overdose presenting to emergency department. Randomized to routine 50 g activated charcoal vs no charcoal.
Routine administration of charcoal following oral overdose did NOT significantly influence length of stay or other patient outcomes. Few adverse events. Established that indiscriminate use of charcoal in all overdoses is not justified — selective use based on toxin and timing is the appropriate approach. Foundational evidence for current selective-use protocols.
Combined in vivo and in vitro studies (Hall RG Jr, Thompson H, Strother A 1981, Am J Gastroenterol 75(3):192-196, PMID 3917957).
Healthy volunteers consuming gas-producing meals (bean-based) with and without activated charcoal. Breath hydrogen excretion and flatus passage measured.
Activated charcoal reduced intestinal gas production after ingestion of beans as evidenced by decreased breath hydrogen excretion and decreased passage of flatus. Foundational evidence for the FDA-approved over-the-counter use of activated charcoal for occasional gas relief — though magnitude of effect is modest.